Transcatheter Stent Placement for Bilateral Pulmonary Artery Stenosis Due to Idiopathic Fibrosing Mediastinitis
Related Experiment Video
Updated: Jan 27, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Ashraf Haidarah1, Hussam Alsawidi1, Chen Mao1
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Background:
Fibrosing mediastinitis is a rare critical disease that encases and compresses mediastinal structures. It is classified as either primary (idiopathic) or secondary based on the underlying etiology. Idiopathic fibrosing mediastinitis presents significant diagnostic challenges, particularly when patients presented with nonspecific symptoms, which may result in misdiagnosis.
Case Report:
A 53-year-old male patient with bilateral pulmonary artery stenosis due to idiopathic fibrosing mediastinitis was successfully treated with balloon angioplasty and bilateral stent implantation. Subsequent follow-up visits over 3 years demonstrated sustained improvement in the patient's symptoms. Imaging studies confirmed the complete patency of the implanted stents, with no evidence of vascular defects or in-stent restenosis.
Conclusion:
Achieving an accurate diagnosis is critical in these cases; furthermore, transcatheter stent implantation is an effective intervention for managing vascular stenosis associated with fibrosing mediastinitis.Clinical ImpactThe rarity of idiopathic fibrosing mediastinitis and the lack of evidence-based treatment strategies make the diagnosis and management challenging. This case emphasizes the importance of endovascular intervention and underscores its role as a viable treatment option for managing similar cases of pulmonary artery stenosis due to fibrosing mediastinitis.
More Related Videos
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Mitral Stenosis I: Introduction
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...